The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by APG Asset Management US Inc.

APG Asset Management US Inc. raised its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,841 shares of the medical device company’s stock after purchasing an additional 1,357 shares during the period. APG Asset Management US Inc.’s holdings in Cooper Companies were worth $4,910,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in COO. Point72 Europe London LLP lifted its position in shares of Cooper Companies by 4.2% during the second quarter. Point72 Europe London LLP now owns 167,452 shares of the medical device company’s stock worth $14,619,000 after purchasing an additional 6,700 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in Cooper Companies during the second quarter valued at approximately $3,619,000. Toronto Dominion Bank bought a new position in Cooper Companies during the 2nd quarter worth approximately $5,052,000. Squarepoint Ops LLC grew its position in shares of Cooper Companies by 422.9% in the 2nd quarter. Squarepoint Ops LLC now owns 163,787 shares of the medical device company’s stock worth $14,299,000 after acquiring an additional 132,464 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Cooper Companies by 480.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 937,806 shares of the medical device company’s stock valued at $81,870,000 after acquiring an additional 776,140 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on COO shares. Wells Fargo & Company boosted their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Morgan Stanley lifted their target price on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a research note on Tuesday, September 10th. Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and increased their price target for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Finally, Piper Sandler boosted their price objective on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $115.00.

Cooper Companies Trading Up 1.0 %

NASDAQ:COO opened at $109.54 on Friday. The stock has a market cap of $21.82 billion, a PE ratio of 64.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.98. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. The stock’s 50-day moving average is $99.46 and its two-hundred day moving average is $95.75.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same period in the previous year, the firm posted $0.84 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Brian G. Andrews sold 24,788 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is owned by insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.